A revolutionary therapeutic approach for psoriasis: bispecific biological agents

A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast

(2016) Andrea Chiricozzi et al.   Expert Review of Clinical Immunology

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

(2015) Diamant Thaçi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

(2015) Michela Silacci et al.   mAbs

AZ17: a new bispecific drug targeting IL-6 and IL-23 with potential clinical use—improves psoriasis in a human xenograft transplantation model

(2015) Karin Stenderup et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling

(2014) A. Johnston et al.   BRITISH JOURNAL OF DERMATOLOGY

PASI90 response: the new standard in therapeutic efficacy for psoriasis

(2014) L. Puig   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model

(2014) Andrea Chiricozzi et al.   PLoS One

Combined Inhibition of Tumor Necrosis Factor α and Interleukin-17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody

(2014) Jens A. A. Fischer et al.   Arthritis & Rheumatology

The effect of adalimumab on key drivers in the pathogenesis of psoriasis

(2013) A.G.M. Hendriks et al.   BRITISH JOURNAL OF DERMATOLOGY

Biologic fatigue in psoriasis

(2013) Ethan C. Levin et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses

(2013) Michelle A. Lowes et al.   TRENDS IN IMMUNOLOGY

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

(2012) James G. Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis

(2010) Andrea Chiricozzi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A dual-targeting PDGFRβ/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo

(2010) Robert Mabry et al.   mAbs

Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes

(2009) Lisa C. Zaba et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY